Recurrence pattern and prognosis in low-risk breast cancer patients - Data from the DBCG 89-A programme

Acta Oncologica

Volumn 47, Issue 4, 2008, Pages 691-703

  Christiansen, Peer ^a   Al Suliman, Nidal ^b   Bjerre, Karsten ^a   Møller, Susanne ^b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGISTRY; CANCER RISK; CANCER SURGERY; DATA ANALYSIS; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL TIME; BREAST TUMOR; DENMARK; INCIDENCE; MIDDLE AGED; PATHOLOGY; RISK FACTOR; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; BREAST NEOPLASMS; DENMARK; FEMALE; HUMANS; INCIDENCE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 45149115084     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860802056594     Document Type: Article

References (21)

1. Møller S, Jensen MB, Ejlertsen B, Bjerre KD, Larsen M, Hansen HB, et al. The clinical database of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise. Acta Oncol 2008;47:506-24.
2. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991;19:403-10.
3. Hudis CA, Barlow WE, Costantino JP, Gray RJ, Pritchard KI, Chapman JA, et al. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol 2007;25:2127-32.
4. Gray RA. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 2008;16:1141-54.
5. Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;366:2087-106.
6. Axelsson CK, Andersen JA, Andersen KW, Blichert-Toft M, Dombernowsky P, Hansen M, et al. [Prognosis after surgical treatment of breast cancer. 3. The low-risk group of the DBCG (Danish Breast Cancer Cooperative Group)]. Ugeskr Laeger 1991;153:2276-9.
7. Kroman N, Holtveg H, Wohlfahrt J, Jensen MB, Mouridsen HT, Blichert-Toft M, et al. Effect of breast-conserving therapy versus radical mastectomy on prognosis for young women with breast carcinoma. Cancer 2004;100:688-93.
8. de la Rochefordiere A, Asselain B, Campana F, Scholl SM, Fenton J, Vilcoq JR, et al. Age as prognostic factor in premenopausal breast carcinoma. Lancet 1993;341:1039-43.
9. Aebi S, Gelber S, Castiglione-Gertsch M, Gelber RD, Collins J, Thurlimann B, et al. Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet 2000;355:1869-74.
10. Bollet MA, Sigal-Zafrani B, Mazeau V, Savignoni A, de la RA, Vincent-Salomon A, et al. Age remains the first prognostic factor for loco-regional breast cancer recurrence in young (<40 years) women treated with breast conserving surgery first. Radiother Oncol 2007;82:272-80.
11. Zhou P, Gautam S, Recht A. Factors affecting outcome for young women with early stage invasive breast cancer treated with breast-conserving therapy. Breast Cancer Res Treat 2007;101:51-7.
12. Blichert-Toft M, Nielsen M, Düring M, Møller S, Rank F, Overgaard M, et al. Long term results of breast conserving surgery vs. mastectomy for early stage invaqsive breast cancer: 20-year follow-up of the Danish randomized DBCG-82 TM protocol. Acta Oncol 2008;47:672-81.
13. Overgaard M, Christiansen P. The role of local management in locally recurrent and metastatic breast cancer. EJC supplements 2003;1:265-73.
14. van Tienhoven G, Voogd AC, Peterse JL, Nielsen M, Andersen KW, Mignolet F, et al. Prognosis after treatment for loco-regional recurrence after mastectomy or breast conserving therapy in two randomised trials (EORTC 10801 and DBCG-82TM). EORTC Breast Cancer Cooperative Group and the Danish Breast Cancer Cooperative Group. Eur J Cancer 1999;35:32-8.
15. Storm HH, Jensen OM. Risk of contralateral breast cancer in Denmark 1943-80. Br J Cancer 1986;54:483-92.
16. Broet P, de la RA, Scholl SM, Fourquet A, Mosseri V, Durand JC, et al. Contralateral breast cancer: annual incidence and risk parameters. J Clin Oncol 1995;13:1578-83.
17. Vaittinen P, Hemminki K. Risk factors and age-incidence relationships for contralateral breast cancer. Int J Cancer 2000;88:998-1002.
18. Li CI, Malone KE, Porter PL, Daling JR. Epidemiologic and molecular risk factors for contralateral breast cancer among young women. Br J Cancer 2003;89:513-8.
19. Mellemkjaer L, Friis S, Olsen JH, Scelo G, Hemminki K, Tracey E, et al. Risk of second cancer among women with breast cancer. Int J Cancer 2006;118:2285-92.
20. Andersson M, Jensen MB, Engholm G, Storm HH. Risk of second primary cancer among patients with early operable breast cancer registered or randomised in Danish Breast Cancer cooperative Group (DBCG) protocols of the 77, 82 and 89 programmes during 1977-2001. Acta Oncol 2008;47:755-64.
21. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007;18:1133-44.